With the pricing ball in Gilead’s court, ICER offers some parameters on how it can be played — analyst sees at least '$1B in theory'

Amber Tong

When asked directly on Gilead’s recent earnings call whether the company expects to profit from remdesivir — the only antiviral to have generated positive clinical …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With the pricing ball in Gilead’s court, ICER offers some parameters on how it can be played — analyst sees at least '$1B in theory'

Amber Tong

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Acadia snaps up an essential tremor drug after field's summer setbacks

With the pric­ing ball in Gilead’s court, ICER of­fers some pa­ra­me­ters on how it can be played — an­a­lyst sees at least '$1B in the­o­ry'

Amber Tong

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

With the pricing ball in Gilead’s court, ICER offers some parameters on how it can be played — analyst sees at least '$1B in theory'

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Acadia snaps up an essential tremor drug after field's summer setbacks